Towards enhancing therapeutic glycoprotein bioproduction: Interventions in the PI3K/AKT/mTOR pathway

Mohamed Mahameed; Afnan Sulieman; Duah Alkam; Boaz Tirosh

doi:10.1247/csf.19013

Towards enhancing therapeutic glycoprotein bioproduction: Interventions in the PI3K/AKT/mTOR pathway

Mohamed Mahameed
, Afnan Sulieman
, Duah Alkam
, Boaz Tirosh^*

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Short survey › peer-review

4 Scopus citations

Abstract

Recombinant glycoproteins produced in mammalian cells are clinically indispensable drugs used to treat a broad spectrum of diseases. Their bio-manufacturing process is laborious, time consuming, and expensive. Investment in expediting the process and reducing its cost is the subject of continued research. The PI3K/Akt/ mTOR signaling pathway is a key regulator of diverse physiological functions such as proliferation, global protein, and lipid synthesis as well as many metabolic pathways interacting to increase secretory capabilities. In this review we detail various strategies previously employed to increase glycoprotein production yields via either genetic or pharmacological over-activation of the PI3K/Akt/mTOR pathway, and we discuss their potential and limitations.

Original language	English
Pages (from-to)	75-83
Number of pages	9
Journal	Cell Structure and Function
Volume	44
Issue number	2
DOIs	https://doi.org/10.1247/csf.19013
State	Published - 2019

Bibliographical note

Publisher Copyright:
© 2019 The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 9 Industry, Innovation, and Infrastructure

Keywords

CRISPR
MTORC1
Specific productivity
Translation

Access to Document

10.1247/csf.19013

Cite this

@article{4e3e11db4f814ab29a14a6a8ae2924ba,

title = "Towards enhancing therapeutic glycoprotein bioproduction: Interventions in the PI3K/AKT/mTOR pathway",

abstract = "Recombinant glycoproteins produced in mammalian cells are clinically indispensable drugs used to treat a broad spectrum of diseases. Their bio-manufacturing process is laborious, time consuming, and expensive. Investment in expediting the process and reducing its cost is the subject of continued research. The PI3K/Akt/ mTOR signaling pathway is a key regulator of diverse physiological functions such as proliferation, global protein, and lipid synthesis as well as many metabolic pathways interacting to increase secretory capabilities. In this review we detail various strategies previously employed to increase glycoprotein production yields via either genetic or pharmacological over-activation of the PI3K/Akt/mTOR pathway, and we discuss their potential and limitations.",

keywords = "CRISPR, MTORC1, Specific productivity, Translation",

author = "Mohamed Mahameed and Afnan Sulieman and Duah Alkam and Boaz Tirosh",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

doi = "10.1247/csf.19013",

language = "אנגלית",

volume = "44",

pages = "75--83",

journal = "Cell Structure and Function",

issn = "0386-7196",

publisher = "Japan Society for Cell Biology",

number = "2",

}

TY - JOUR

T1 - Towards enhancing therapeutic glycoprotein bioproduction

T2 - Interventions in the PI3K/AKT/mTOR pathway

AU - Mahameed, Mohamed

AU - Sulieman, Afnan

AU - Alkam, Duah

AU - Tirosh, Boaz

PY - 2019

Y1 - 2019

N2 - Recombinant glycoproteins produced in mammalian cells are clinically indispensable drugs used to treat a broad spectrum of diseases. Their bio-manufacturing process is laborious, time consuming, and expensive. Investment in expediting the process and reducing its cost is the subject of continued research. The PI3K/Akt/ mTOR signaling pathway is a key regulator of diverse physiological functions such as proliferation, global protein, and lipid synthesis as well as many metabolic pathways interacting to increase secretory capabilities. In this review we detail various strategies previously employed to increase glycoprotein production yields via either genetic or pharmacological over-activation of the PI3K/Akt/mTOR pathway, and we discuss their potential and limitations.

AB - Recombinant glycoproteins produced in mammalian cells are clinically indispensable drugs used to treat a broad spectrum of diseases. Their bio-manufacturing process is laborious, time consuming, and expensive. Investment in expediting the process and reducing its cost is the subject of continued research. The PI3K/Akt/ mTOR signaling pathway is a key regulator of diverse physiological functions such as proliferation, global protein, and lipid synthesis as well as many metabolic pathways interacting to increase secretory capabilities. In this review we detail various strategies previously employed to increase glycoprotein production yields via either genetic or pharmacological over-activation of the PI3K/Akt/mTOR pathway, and we discuss their potential and limitations.

KW - CRISPR

KW - MTORC1

KW - Specific productivity

KW - Translation

UR - https://www.scopus.com/pages/publications/85070767931

U2 - 10.1247/csf.19013

DO - 10.1247/csf.19013

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.shortsurvey???

C2 - 31353334

AN - SCOPUS:85070767931

SN - 0386-7196

VL - 44

SP - 75

EP - 83

JO - Cell Structure and Function

JF - Cell Structure and Function

IS - 2

ER -

Towards enhancing therapeutic glycoprotein bioproduction: Interventions in the PI3K/AKT/mTOR pathway

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this